Tom Powles: Terry Friedlander highlights multiple factors why SG did not beat chemotherapy in UC
Tom Powles, Professor at the University of London, shared a post on X:
“TROPICS4 discusses by Terry Friedlander highlights multiple factors why SG did not beat chemotherapy in UC.
The pursuit of biomarkers, better patient selection and education around tox is important. Other agents in the same class, with different linkers and ADRs may be advantageous.”
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals.
His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
More posts featuring Tom Powles.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023